Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic analysis of cerebellum of hepatic encephalopathy rat model

ABSTRACT: Hepatic Encephalopathy is the brain disorder caused by liver damage, characterized by cognitive and motor impairments. Glutamate a predominant excitatory neurotransmitter over activate post-synaptic neuron via NMDAR receptors leads to neuronal derangement. NMDAR as a therapeutic target is not viable option due to its crucial role in brain physiology. In order to discover new non-NMDAR therapeutic targets high resolution mass spectrometry (HRMS) technique was used for proteomic profiling of MoHE rat’s model.

INSTRUMENT(S):

ORGANISM(S): Rattus Norvegicus (rat)

TISSUE(S): Cerebellum

DISEASE(S): Hepatic Encephalopathy

SUBMITTER: Papia Acharjee

LAB HEAD: Papia Acharjee

PROVIDER: PXD036573 | Pride | 2026-04-29

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	21092021_Fusion_BHU_Control_1-009.msf	Msf
	21092021_Fusion_BHU_Control_1-010.pdResult	Other
	21092021_Fusion_BHU_Control_1.raw	Raw
	21092021_Fusion_BHU_Control_2.raw	Raw
	21092021_Fusion_BHU_Control_3.raw	Raw

Items per page:

1 - 5 of 14

Similar Datasets

Proteomic analysis of hippocampal proteins in moderate hepatic encephalopathy rat model

Project description:Hepatic Encephalopathy is the brain disorder caused by liver damage, characterized by cognitive and motor impairments. Glutamate a predominant excitatory neurotransmitter over activate post-synaptic neuron via NMDAR receptors leads to neuronal derangement. NMDAR as a therapeutic target is not viable option due to its crucial role in brain physiology. In order to discover new non-NMDAR therapeutic targets high resolution mass spectrometry (HRMS) technique was used for proteomic profiling of the hippocampal proteins in Moderate hepatic encephalopathy (MoHE) rat model.

2024-05-27 | PXD036723 | Pride

Photoactivated adenylyl cyclase in cortical astrocytes promotes synaptic potentiation and reveals alterations in Huntington’s Disease

Project description:Astrocytes are glial cells essential for neuronal plasticity. However, the role of astrocytic cAMP signalling in brain activity and function is still missing. We expressed DdPAC, a photoactivated adenylyl cyclase that increases cAMP upon red light, in cortical astrocytes to investigate its effects. We assessed synaptic transmission using multi-electrode arrays, and molecular changes through proteomic, phosphoproteomic, and metabolic analyses. We also measured brain hemodynamics and analysed motor behaviour in wild-type (WT) and R6/1 Huntington's disease (HD) mice. DdPAC stimulation in cortical astrocytes induced long-term synaptic potentiation in WT mice, which was PKA and NMDAR-dependent but Ca2+-independent. It also triggered PKA-signalling pathways and modulated synaptic and morphology-associated proteins. Further, cAMP signalling increased cortical blood flow and improved motor learning in WT mice but show differential responses in HD mice. Our results unravel the impact of cAMP signalling in astrocytes to synaptic to brain function, and highlight its alterations in HD.

2025-09-18 | PXD054633 | Pride

Photoactivated adenylyl cyclase in cortical astrocytes promotes synaptic potentiation and reveals alterations in Huntington’s Disease

2025-09-18 | PXD054635 | Pride

ASO-treated Shank3 HT mice proteome

Project description:Decreased NMDA receptor function is a central mechanism implicated in various brain disorders, and extensive efforts to modulate NMDAR activity have been devoted in various therapeutic settings. We have previously established Slc6a20a as a novel glycine transporter, and using an antisense oligonucleotide ASO against Slc6a20a, we sought to modulate NMDAR function in well-established models of psychiatric disorders Shank2 and Shank3 mutant mice.

2026-04-24 | PXD061255 | Pride

ASO-treated Shank2 KO mice total proteomic data

2026-04-24 | PXD061252 | Pride

ASO-treated Shank3 KO mice phosphoproteome

2026-04-24 | PXD061261 | Pride

ASO-treated Shank3 HT mice phosphoproteome

2026-04-24 | PXD061258 | Pride

ASO treated adult Shank2 KO mice phosphoproteome

2026-04-24 | PXD061254 | Pride

CYFIP1 dosages exhibit divergent behavioral impact via diametric regulation of NMDAR complex translation in mouse models of psychiatric disorders

Project description:Gene dosage imbalance caused by copy number variations (CNVs) are prominent contributors to brain disorders. 15q11.2 CNV duplications and deletions have been associated with autism spectrum disorder (ASD) and schizophrenia (SCZ), respectively. The mechanism underlying these diametric contributions remain unclear. Here we established both loss-of-function and gain-of-function mouse models of Cyfip1, one of four genes within 15q11.2 CNVs and these mice exhibited both distinct and shared behavioral abnormalities related to ASD and SCZ. RIP-seq analysis identified mRNA targets of CYFIP1 in vivo, including postsynaptic NMDAR complex components. These mouse models showed diametric changes in levels of postsynaptic NMDAR complex components at synapses due to dysregulated protein translation, resulting in bidirectional alteration of NMDAR-mediated signaling. Importantly, pharmacological balancing of NMDAR signaling in mouse models with diametric CYFIP1 dosages rescues behavioral abnormalities. Our integrated analyses provide insight into how gene dosage imbalance caused by CNVs may contribute to divergent neuropsychiatric disorders.

2022-02-02 | GSE166939 | GEO

NMDA glutamate receptor antagonist MK-801 induces proteome changes in adult human brain slices which are partially counteracted by haloperidol and clozapine

Project description:Deciphering the molecular pathways associated with N-methyl-D-aspartate receptor (NMDAr) hypofunction and its interaction with antipsychotics is necessary to advance our understanding of the basis of schizophrenia, as well as our capacity to treat this disease. In this regard, the development of human brain-derived models amenable for studying the neurobiology of schizophrenia may contribute to fill the gaps led by the widely employed animal models. Here we assessed the proteomic changes induced by the NMDA glutamate receptor antagonist MK-801 on human brain slice cultures obtained from adult donors submitted to resective neurosurgery. Initially, we demonstrated that MK-801 diminishes NMDA glutamate receptor signaling in human brain slices in culture. Next, using mass- spectrometry-based proteomics and systems biology in silico analyses, we found that MK-801 led to alterations in proteins related to several pathways previously associated with schizophrenia pathophysiology including ephrin, opioid, melatonin, sirtuin signaling, interleukin 8, endocannabinoid and synaptic vesicle cycle. We also evaluated the impact of both typical and atypical antipsychotics on MK-801-induced proteome changes. Interestingly, the atypical antipsychotic clozapine showed a more significant capacity to counteract the protein alterations induced by NMDAr hypofunction than haloperidol. Finally, using our dataset we identified potential modulators of the MK-801-induced proteome changes, which may be considered promising targets to treat NMDAr hypofunction in schizophrenia.

2024-02-06 | PXD046944 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data